Skip to content

Biogen Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: October 28, 2026 results vs estimates

Biogen Inc · E.BIIB.NASDAQ · United States
Use symbol E.BIIB.NASDAQ in our API & Excel add-in to retrieve this data ↓
249.65
(+0.02%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 50%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 33.63%

Biogen Inc Forecast

Biogen Inc short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 33.6% a year, a typical one-standard-deviation range is 237.82–261.48 over a week, 225.42–273.88 over a month and 165.70–333.60 over a year. (Signals as of 1 Nov 2026.)

Biogen Inc Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
Biogen Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Biogen Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Biogen Inc
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Biogen Inc
P/E
106.18x
Stretched vs own history
QoQ +174.9%
YoY +562.3%
now 106.182115.04 low107.87 high
ⓘP/E As of 22 Nov 2026.See Biogen Inc returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Biogen Inc
P/S
3.58x
Mid-range vs own history
QoQ +11.5%
YoY +39.9%
now 3.58332.4 low3.72 high
ⓘP/S As of 22 Nov 2026.See Biogen Inc returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Biogen Inc
P/B
1.95x
Mid-range vs own history
QoQ +14.0%
YoY +37.7%
now 1.951.33 low1.98 high
ⓘP/B As of 22 Nov 2026.See Biogen Inc returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Biogen Inc
EV/EBITDA
27.06x
Stretched vs own history
QoQ +45.3%
YoY +232.7%
now 27.06147.68 low27.43 high
ⓘEV/EBITDA As of 22 Nov 2026.See Biogen Inc returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Biogen Inc
EV/Sales
4.21x
Stretched vs own history
QoQ +7.5%
YoY +49.3%
now 4.21432.66 low4.42 high
ⓘEV/Sales As of 22 Nov 2026.See Biogen Inc returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Biogen Inc
FCF Yield
5.6%
Mid-range vs own history
QoQ −33.0%
YoY −36.7%
now 5.56775.48 low9.37 high
ⓘFCF Yield As of 22 Nov 2026.See Biogen Inc returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Biogen Inc
Earnings Yield
0.9%
Weak vs own history
QoQ −63.6%
YoY −84.9%
now 0.94180.93 low6.65 high
ⓘEarnings Yield As of 22 Nov 2026.See Biogen Inc returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Biogen Inc
Market Cap
$36.9B
Mid-range vs own history
QoQ +14.5%
YoY +43.1%
now 36898.2724,186 low37,485 high
ⓘMarket Cap As of 22 Nov 2026.See Biogen Inc returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Biogen Inc
Net Debt
$6.5B
High vs own history
QoQ −8.1%
YoY +147.1%
now 6497.42,279 low7,070 high
ⓘNet Debt As of 22 Nov 2026.See Biogen Inc returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Biogen Inc
Net Debt / EBITDA
4.05x
High vs own history
QoQ +21.0%
YoY +438.3%
now 4.05180.75 low4.05 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Biogen Inc returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Biogen Inc
Current Ratio
1.95x
Mid-range vs own history
QoQ +4.3%
YoY −28.4%
now 1.94551.87 low3.06 high
ⓘCurrent Ratio As of 22 Nov 2026.See Biogen Inc returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Biogen Inc
Quick Ratio
1.37x
Mid-range vs own history
QoQ +9.4%
YoY −32.8%
now 1.37491.26 low2.41 high
ⓘQuick Ratio As of 22 Nov 2026.See Biogen Inc returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Biogen Inc
Interest Coverage
2.37x
Weak vs own history
QoQ −46.8%
YoY −77.5%
now 2.36732.37 low10.5 high
ⓘInterest Coverage As of 22 Nov 2026.See Biogen Inc returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Biogen Inc
Debt / Equity
0.41x
Mid-range vs own history
QoQ −7.0%
YoY +13.9%
now 0.41230.35 low0.44 high
ⓘDebt / Equity As of 22 Nov 2026.See Biogen Inc returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Biogen Inc
Piotroski F-Score
3
Weak vs own history
QoQ 0.0%
YoY −57.1%
now 33 low7 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Biogen Inc returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Biogen Inc
Altman Z-Score
3.13
Mid-range vs own history
QoQ +6.4%
YoY −4.4%
now 3.13442.85 low3.58 high
ⓘAltman Z-Score As of 22 Nov 2026.See Biogen Inc returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  19 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  21 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Biogen Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Biogen Inc fundamentals: income statement, balance sheet & cash flow

Biogen Inc reported revenue of $9.89bn and net income of $1.29bn in FY2025, the year ended 31 December 2025 — revenue up 2.2% and net income down 20.8% on the prior year. Free cash flow was $2.05bn. These figures are as reported in the filings, not restated: 41 fiscal years and 165 quarters of history, back to December 1985. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$9.89bn
+2.2%
Net income
$1.29bn
-20.8%
Gross margin
75.69%
Free cash flow
$2.05bn
-18.5%
Net debt
$3.94bn
Shares short (30 Oct 2026)
5.45m
3.96 days to cover
Biogen Inc income statement, annual, as reported · USD billions unless stated
USD billionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue9.899.689.8410.1710.98
Cost of revenue2.402.312.532.282.11
Gross profit7.497.377.307.908.87
Research & development1.782.492.702.603.40
Operating income2.472.492.102.892.79
EBITDA2.603.002.383.543.92
Interest expense0.270.250.250.250.25
Pre-tax income1.561.911.303.591.78
Income tax0.260.270.140.630.05
Net income1.291.631.163.051.56

Download Biogen Inc fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.BIIB.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 41 fiscal years and 165 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Biogen Inc

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Biogen Inc Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Biogen Inc; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Biogen Inc’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Biogen Inc behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Biogen Inc (United States)

Biogen Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Biogen Inc

Frequently asked questions

What is Biogen Inc?
Biogen Inc is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Biogen Inc price?
The latest close is 249.65 (1 Nov 2026), +0.02% on the day. The price at the top of the page refreshes during the trading day.
Is Biogen Inc in an uptrend?
As of 1 Nov 2026, short-term momentum is positive (3 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Biogen Inc?
20-day realised volatility is 33.6% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 9.7% over a month and 4.7% over a week.
What factors affect Biogen Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Biogen Inc, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Biogen Inc?
58 backtested tactical asset allocation strategies trade Biogen Inc through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Biogen Inc returns analysed?
The Statistical Distribution of Returns section shows the distribution of Biogen Inc daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Biogen Inc historical data?
In the Free historical data section of this page: the last 10 years of Biogen Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Biogen Inc historical data (last 10 years)

Browse or instantly download the last 10 years of Biogen Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.BIIB.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20249.59
2026-11-19247.13
2026-11-18251.41
2026-11-17250.79
2026-11-16251.65
2026-11-13253.4
2026-11-12250.48
2026-11-11253.4
2026-11-10253.25
2026-11-09254.87
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.